Logistics provider DHL Group announced recently it had purchased 100 percent of CRYOPFP, a specialty courier, from Cryoport, Inc.
CRYOPDP provides logistics services for clinical trials, biopharma, and cell and gene therapies. The company said the acquisition will enhance its capabilities in specialty pharma logistics, while helping it to form a strategic partnership with Cryoport to strengthen both companies’ supply chain services offerings.
“The acquisition of CRYOPDP is a pivotal move for our supply chain business as we aim to expand our Pharma Specialized Network to meet the evolving needs of clinical trials, biopharma and cell & gene therapies, in addition to further increasing our footprint in the conventional pharma and life science healthcare segment,” Oscar de Bok, CEO of DHL Supply Chain, said. “The acquisition of CRYOPDP and the extended partnership with Cryoport Inc. will enable us to deliver integrated end-to-end solutions, enhancing our service capabilities.”
DHL said CRYOPDP provides white-glove courier services for the sectors it serves with operations in 15 countries. CRYOPDP handles more than 600,000 shipments per year, and services customers and patients in more than 135 countries worldwide.
“We are indeed pleased to build on our trusted relationship with the DHL Group,” Jerrell Shelton, CEO of Cryoport, said. “Working together we will bring an enhanced set of supply chain solutions to meet companies’ and patients’ critical supply chain needs. This strategic partnership taps into the strong expertise of DHL’s Supply Chain and CRYOPDP, presenting a substantial opportunity for Cryoport to further expand its reach to global growth markets such as Asia Pacific (APAC) and Europe, Middle East and Africa (EMEA).”